安科生物：公司生长激素新患入组同期保持了增长，生长激素水针占公司整体生长激素产品比例持续增长

Core Viewpoint - Anke Biological (300009) reported on October 29 that the company's growth hormone new patient enrollment has continued to increase, with the water injection form of growth hormone accounting for a growing proportion of the overall growth hormone product line, enhancing the company's product competitiveness and contributing to profit growth [1] Group 1 - The company has seen a continuous increase in new patient enrollment for its growth hormone products [1] - The water injection form of growth hormone is becoming a larger part of the company's overall growth hormone product portfolio [1] - The increase in product competitiveness is expected to lead to profit growth for the company [1]